期刊文献+

CYP2C9和VKORC1基因多态性与华人华法林用药量的关联 被引量:10

下载PDF
导出
摘要 华法林是一种临床上广泛使用的香豆素类抗凝药。其治疗窗窄,用药剂量个体差异大,且容易发生溶血或血栓塞。华人所需要的华法林剂量远低于高加索人,这其中的差异与CYP2C9和VKORC1两个基因的多态性相关。其中,VKORC1基因是影响华法林需求剂量种族差异和个体差异的主要因素。目前,国内外学者已构建了基于不同种族和人群的华法林剂量预测模型,这为华法林的临床个体化用药提供依据和保障。该文从CYP2C9和VKORC1基因多态性与华人华法林用药量关联,以及基于华裔人群构建的华法林剂量预测模型两方面综述最新研究进展,以期为华法林的个体化治疗提供参考和理论依据。
出处 《医药导报》 CAS 2015年第6期775-779,共5页 Herald of Medicine
基金 武汉市卫生局科研项目(WX13B28)
  • 相关文献

参考文献44

  • 1YIN T, MIYATA T. Warfarin dose and the pharmacogen- omics of CYP2C9 and VKORCl-rationale and perspectives [J]. Thromb Res,2007,120( 1 ) :1-10.
  • 2LOEBSTEIN R, YONATH H, PELEG D, et al. Interindi- vidual variability in sensitivity to warfarin-Nature or nurture? [J]. Clin Pharm Ther,2001,70(2) :159-164.
  • 3CONSORTIUM I W P. Estimation of the warfarin dose with clinical and pharmacogenetic data [ J ]. New Engl J Med, 2009,360 ( 8 ) : 753.
  • 4WADELIUS M, PIRMOHAMED M. Pharmacogenetics of warfarin: current status and future challenges [ J ]. Pharmacogenomics J, 2007,7 ( 2 ) : 99-111.
  • 5CHA P C, MUSHIRODA T, TAKAHASHI A, et al. Genome- wide association study identifies genetic determinants of warfarin responsiveness for Japanese [ J ]. Hum Mol Genet, 2010,19(23) :4735-4744.
  • 6TAKEUCHI F,MCGINNIS R, BOURGEOIS S,et al. A geno- me-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose [ J ]. PLoS Genetics ,2009,5 ( 3 ) : e1000433.
  • 7BRECKENRIDGE A, ORME M, WESSELING H, et al. Pha- rmacokinetics and pharmacodynamics of the enantiomers of warfarin in man [J]. Clin Pharm Ther,1974,15 (4) :424- 430.
  • 8TAKAHASHI H, ECHIZEN H. Pharmacogenetics of warfarin elimination and its clinical implications [ J ]. Clin Pharm, 2001,40(8) :587-603.
  • 9GOODSTADT L, PONTING C P. Vitamin K epoxide reduc- tase : homology, active site and catalytic mechanism [ J ]. Trends Biochem Sci,2004,29 ( 6 ) : 289-292.
  • 10YUAN H Y, CHEN J J, LEE M M, et al. A novel functional VKORC1 promoter polymorphism is associated with inter- individual and inter-ethnic differences in warfarin sensitivity [ J]. Hum Mol Genet,2005,14 ( 13 ) : 1745-1751.

二级参考文献77

  • 1卫生部合理用药专家委员会.中国医师药师临床用药指南[M].重庆:重庆出版集团重庆出版社,2009:700-701.
  • 2Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent ad- verse effect resulting in regulatory action[J]. Arch Intern Med, 2007, 167(13): 1414-1419.
  • 3Klein TE, Altman RB, Eriksson N,et al. Estima- tion of the warfarin dose with clinical and pharma- cogenetic data[J]. N EnglJ Med, 2009, 360(8): 753-764.
  • 4Gage BF, Eby C, Johnson JA,et al. Use of phar- maeogenetic and clinical faetors to predict the ther- apeutic dose of warfarin[J]. Clin Pharmacol Ther, 2008, 84(3): 326-331.
  • 5Wen MS, Lee M, Chen JJ,et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes [J]. Clin Pharmacol T- her, 2008, 84(1): 83-89. pharmacogenetic algorithms.
  • 6Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindi- vidual warfarin maintenance dose: a prospective study in Chinese patients[J]. Pharmacogenet Ge- nomics, 2009, 19(3): 226-234.
  • 7Wadelius M, Chen LY, Lindh JD,et al. The largest prospective warfarin treated cohort supports genet- ic forecasting[J]. Blood, 2009, 113(4): 784- 792.
  • 8Marin-Leblanc M, Perreault S, Bahroun I, et al. Validation of warfarin in clinical praetice[J]. Pharmacogenomics, 2012, 13(1): 21-29.
  • 9Liu Y, Yang J, Xu Q,et al. Comparative perform ance of warfarin pharmacogenetic algoritlams in Chinese patients[J]. Thromb Res, 2012.
  • 10Cho H J, On YK, Bang OY, et al. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation[J]. Clin Ther, 2011, 33(10): 1371-1380.

共引文献60

同被引文献126

引证文献10

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部